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Purpose or Objective: The prophylactic inguinal lymph-
nodes (LNs) radiotherapy (RT) is considered the standard 
treatment, however it implies more toxicity. Moreover, 
inguinal recurrence occurs in 0%-12% of T1-T2, and 19%-30% 
of T3-T4 patients (pts) who did not receive prophylactic 
inguinal RT. So, 70%-81% of T3-T4 pts are uselessly irradiated, 
and 0%-12% of T1-T2 pts should be treated. An improvement 
of staging is mandatory. Aim of this study is to evaluate the 
role of sentinel lymph-node biopsy (SLNB) in staging and 
treatment of pts with anal cancer.  
 
Material and Methods: Patients with squamous cell 
carcinoma of anal canal were staged with physical 
examination, endoscopy, chest and abdomen CT, pelvic MR, 
and simulation FDG-PET. Pts without gross inguinal LN 
metastasis were candidate for the lymphoscintigraphy with 
99mTC nanocolloid. The CTV included the GTV (primary 
tumour and positive LNs), mesorectum, internal and common 
iliac LNs. As the inguinal RT was considered standard, the 
radiation oncologists were left free to decide whether 
irradiate this region independently from the clinical stage 
and the SLNB histological results. PTV1 and PTV2 
corresponded to GTV and CTV, respectively, with a margin of 
0.5 cm. Prescribed dose was 50.4Gy in 28 F to the PTV2, and 
64.8Gy in 36 F, as sequential boost, to the PTV1. IMRT or 
Volumetric Modulated Arc Therapy (VMAT) were used. 
Concomitant chemotherapy consisted of 2 cycles of Mito-C 10 
mg/m2, and continuous infusion 5-FU 1000 mg/m2/day for 4 
consecutive days.  
 
Results: From 3/2008 to 2/2014, 48 consecutive pts were 
treated (T1=9, T2=15, T3=16, T4=8). PET was performed in 42 
out of the 48 pts, and 27 out of these 42 pts underwent 
lymphoscintigraphy. Pathologic inguinal uptake was shown in 
15/42 (36%) pts. Lymphoscigraphy was performed in 9 out of 
these 15 pts. Histological examination was performed in 8 pts 
(SLN not found in 1 pt) and confirmed inguinal metastasis in 
3/8 pts (37.5% ) but did not confirmed metastasis in 5 pts 
(62.5%). PET did not show pathologic uptake in 27/42 pts 
(64%). Lymphoscintigraphy was performed in 18 out of these 
27 pts: SLN was not found in 1 pt. Histological examination 
found metastasis in 2/17 (12%) and confirmed the absence of 
metastasis in 15 pts (88%). Thirty-one pts received 
prophylactic or curative RT to the groins, the “Groin group”, 
and 17 pts did not , the “No groin group”. All the 17 pts of 
the “No groin group” underwent SLNB procedure: 16 pts had 
SLNB histologically negative, 1 pt had lymphoscintigraphy 
negative (SLN not found ) and PET negative; two pts with PET 
positive in right inguinal LN but ipsilateral SLNB negative 
were not irradiated. No pt in both groups had inguinal relapse 
or progression. Of note, median follow up duration in the “No 
groin group” was 41 months (19.2-90.7 months). 
 
Conclusion: SLNB can further improve the PET based staging 
and select the “true negative” patients for which the inguinal 
LN irradiation could be avoided. 
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Purpose or Objective: to evaluate efficacy and tolerability 
of stereotactic ablative radiotherapy (SABR) in the treatment 
of patients with colorectal cancer with exclusive 
oligometastases to the lung. 
 
Material and Methods: we treated 62 lung metastases in 38 
patients with oligometastatic colorectal cancer. Inclusion 
criteria were: primary tumor controlled, ≤ 5 lung metastases, 
no other active sites of disease at the time of the SABR. Dose 
prescription was: 23Gy/1 fr per central lesion <30 cc (18 
lesions), 30Gy/1fr for peripheral metastases <30 cc (35 
lesions), 45Gy/3fr for peripheral lesion >30cc (9 lesions). 
Twenty patients had 1 metastasis (53%), 14 patients had 2 
metastases (37%)and 4 patients tree-to-four metastases 
(10%). Median BED was 120 Gy. OS, PFS, MFS, local control 
and toxicity were evaluated. 
 
Results: median follow-up was 24 months (ranged 3-76 mo). 
Median actuarial survival was 34 months (c.i. 20-47 months). 
Overall survival (OS) at 1-, 2- and 5-years was 80%, 50.7% and 
26.9% respectively. Complete response (CR) was achieved in 
22/62 lesions (35.4%). Median disease-free survival (DFS) was 
24 months (ranged 13-34 months). DFS at 1-, 2- and 5-years 
was 79.8% and 40.4% and 22%, respectively. Complete 
response (CR) was the only prognostic factor significantly 
correlated with OS, PFS and metastasis-free survival (MFS) 
(p= 0.001 in each case). Patients with CR had 1-,2- and 5-
years OS of 100%, 90.9% and 67.3%, while patients with 
partial response (PR) and stable disease (SD) had respectively 
69.2, 34.6% and 0% and 63.5% at 1 and 2-years and 15.9% at 
5-years. Acute G1-2 lung toxicity, according to the CTCAE-
V4.0, was 10%, G3 lung toxicity was 1.6%. Late G1-2 toxicity 
rate was 25%. No late G3 toxicity was found. 
 
Conclusion: SABR has a high rate of local control in the lung 
metastasis from colorectal cancer and also affect survival. CR 
statistically correlated with OS, PFS and MFS, even at long-
term. There is a need of prospective trials to confirm these 
data and to identify the right selection criteria and the best 
timing with systemic therapies. 
 
Poster: Clinical track: Gynaecological (endometrium, 
cervix, vagina, vulva)  
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Purpose or Objective: To determine the effect of the time 
interval between external beam radiotherapy (EBRT) and 
hyperthermia (HT) treatments on locoregional recurrence and 
overall survival of patients with cervical cancer. 
 
Material and Methods: This retrospective study included 59 
women with locally advanced (stage IB2-IVA) cervical cancer, 
all treated with radiotherapy and HT. Additional treatment 
with chemotherapy was reason for exclusion. 
Patients received four to five weekly HT treatments 
concurrent with 23-28 fractions (1.8-2.0 Gy) EBRT and a 
brachytherapy boost (20-24Gy). On HT treatment days, HT 
was given after EBRT. The mean time interval between the 
EBRT and HT treatments that were delivered on the same day 
was used to characterize the typical time interval for that 
patient. The median thereof (79.2 minutes) was used to split 
the cohort in a ‘short’ and ‘long’ time-interval group. Median 
time intervals were 65.8 minutes (range 33.8-79.2) and 91.7 
minutes (range 80.0-125.2) for the short and long time-
interval group, respectively.  
Locoregional recurrence and overall survival were estimated 
using Kaplan-Meier analysis, and compared by a log-rank test. 
To correct for any potential confounding factors, a stepwise 
Cox regression analysis using backward elimination was used 
with time-interval group, age, FIGO stage, number of HT 
treatments, tumour temperature during HT treatment (T90), 
lymph node status and smoking as covariates. 
